Featured Press Release
-
1/2/19 7:00 am ESTWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference as follows: Date: Wednesday, January 9, 2019See More
-
11/27/18 6:50 am EST
--Eagle to explore ARS indication to treat individuals exposed to high doses of radiation such as nuclear power plant leakage or nuclear weapons; additional research ongoing to evaluate hematopoietic syndrome in certain cancer patients undergoing radiation therapy--
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced positive results of a proof-of-concept (POC) study in a Total-Body Radiation Animal Model. The objective of the study was to evaluate the efficacy of intravenous administration of RYANODEX® to prevent or mitigate Acute Radiation Syndrome (ARS) in a total body irradiated C57BL/6 male mouse hematopoietic model. Animals inSee More -
11/19/18 7:00 am ESTWOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows: Date: Wednesday, November 28, 2018See More